NEW YORK – September 11, 2026 (STL.News) Biohaven Ltd. (NYSE: BHVN) is facing a new securities investigation after the biotechnology company’s shares fell nearly 15% following disclosure that the U.S. Food and Drug Administration placed a partial clinical hold on new patient enrollment in trials involving its experimental epilepsy treatment BHV-7000, also known as opakalim. Levi & Korsinsky LLP announced Friday that it is investigating potential federal securities law claims on behalf of Biohaven investors. The announcement comes one day after Biohaven shares fell $2.21, or about 14.73%, after the FDA action was disclosed. The latest development is particularly
Source: Read Original Article
